Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.

Literature DB >> 12878541

In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.

Valerie Laganas¹, Jeffrey Alder, Jared A Silverman.

Abstract

Previous studies have suggested that lipoteichoic acid biosynthesis inhibition is the mechanism of action of daptomycin. In this investigation, daptomycin inhibited all macromolecular synthesis in Staphylococcus aureus, Enterococcus faecalis, and Enterococcus hirae without kinetic or dose specificity for lipoteichoic acid. Daptomycin remained bactericidal in the absence of ongoing lipoteichoic acid synthesis. Inhibition of lipoteichoic acid synthesis is apparently not the mechanism of action of daptomycin in these pathogens.

Entities: Chemical Species

Mesh：

Substances：

Year: 2003 PMID： 12878541 PMCID： PMC166111 DOI： 10.1128/AAC.47.8.2682-2684.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

20 in total

1. In vitro bactericidal activity of daptomycin against staphylococci.

Authors: Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal: J Antimicrob Chemother Date: 2002-03 Impact factor: 5.790

2. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint.

Authors: R Wise; J M Andrews; J P Ashby
Journal: J Antimicrob Chemother Date: 2001-10 Impact factor: 5.790

3. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors: A L Barry; P C Fuchs; S D Brown
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

4. Resistance studies with daptomycin.

Authors: J A Silverman; N Oliver; T Andrew; T Li
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

5. A rapid method of total lipid extraction and purification.

Authors: E G BLIGH; W J DYER
Journal: Can J Biochem Physiol Date: 1959-08

6. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.

Authors: A King; I Phillips
Journal: J Antimicrob Chemother Date: 2001-08 Impact factor: 5.790

7. Precursor-product relationship of intracellular and extracellular lipoteichoic acids of Streptococcus faecium.

Authors: R E Kessler; G D Shockman
Journal: J Bacteriol Date: 1979-02 Impact factor: 3.490

8. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors: D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

9. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic.

Authors: E Breukink; I Wiedemann; C van Kraaij; O P Kuipers; H G Sahl; B de Kruijff
Journal: Science Date: 1999-12-17 Impact factor: 47.728

10. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.

Authors: Jared A Silverman; Nancy G Perlmutter; Howard M Shapiro
Journal: Antimicrob Agents Chemother Date: 2003-08 Impact factor: 5.191

26 in total

1. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors: Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2010-10-04 Impact factor: 5.191

Review 2. Nonribosomal peptide synthetases involved in the production of medically relevant natural products.

Authors: Elizabeth A Felnagle; Emily E Jackson; Yolande A Chan; Angela M Podevels; Andrew D Berti; Matthew D McMahon; Michael G Thomas
Journal: Mol Pharm Date: 2008-01-25 Impact factor: 4.939

3. Cardiolipin prevents membrane translocation and permeabilization by daptomycin.

Authors: TianHua Zhang; Jawad K Muraih; Nasim Tishbi; Jennifer Herskowitz; Rachel L Victor; Jared Silverman; Stephanie Uwumarenogie; Scott D Taylor; Michael Palmer; Evan Mintzer
Journal: J Biol Chem Date: 2014-03-10 Impact factor: 5.157

4. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains.

Authors: Anna Müller; Michaela Wenzel; Henrik Strahl; Fabian Grein; Terrens N V Saaki; Bastian Kohl; Tjalling Siersma; Julia E Bandow; Hans-Georg Sahl; Tanja Schneider; Leendert W Hamoen
Journal: Proc Natl Acad Sci U S A Date: 2016-10-24 Impact factor: 11.205

Review 5. Newer treatment options for skin and soft tissue infections.

Authors: Murugan Raghavan; Peter K Linden
Journal: Drugs Date: 2004 Impact factor: 9.546

6. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.

Authors: Bruk Mensa; Gabriella L Howell; Richard Scott; William F DeGrado
Journal: Antimicrob Agents Chemother Date: 2014-06-16 Impact factor: 5.191

7. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors: Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2012-08-20 Impact factor: 5.191